The oversubscribed round was led by Enavate Sciences, part of the Patient Square Capital portfolio, the Boston-based biotech said Wednesday morning. The investor has also backed Sam Waksal’s ROCK2 biotech Graviton Bioscience and TYK2 startup Sudo Biosciences in recent months. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER